Selecta Biosciences (NASDAQ:SELB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
Other equities analysts have also issued reports about the company. BidaskClub lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 27th. Mizuho reiterated a “buy” rating and issued a $30.00 price objective on shares of Selecta Biosciences in a research note on Wednesday, October 17th. Stifel Nicolaus reiterated a “buy” rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. UBS Group set a $6.00 price objective on Selecta Biosciences and gave the stock a “hold” rating in a research note on Friday, November 9th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $23.21.
Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08. On average, research analysts predict that Selecta Biosciences will post -2.92 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in Selecta Biosciences during the third quarter valued at about $196,000. MetLife Investment Advisors LLC bought a new position in Selecta Biosciences during the third quarter valued at about $225,000. Rhumbline Advisers increased its stake in Selecta Biosciences by 43.7% during the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after acquiring an additional 5,103 shares during the period. Virtu Financial LLC bought a new position in Selecta Biosciences during the third quarter valued at about $363,000. Finally, Marshall Wace LLP bought a new position in Selecta Biosciences during the third quarter valued at about $396,000. Hedge funds and other institutional investors own 51.04% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.